Logo image of CAI

CARIS LIFE SCIENCES INC (CAI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CAI - US1421521071 - Common Stock

27.12 USD
+0.7 (+2.65%)
Last: 1/15/2026, 8:00:02 PM
27.12 USD
0 (0%)
After Hours: 1/15/2026, 8:00:02 PM
Fundamental Rating

3

Overall CAI gets a fundamental rating of 3 out of 10. We evaluated CAI against 528 industry peers in the Biotechnology industry. CAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CAI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CAI had negative earnings in the past year.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • The Return On Assets of CAI (-101.38%) is worse than 75.00% of its industry peers.
  • Looking at the Return On Equity, with a value of -208.66%, CAI is doing worse than 68.75% of the companies in the same industry.
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 53.54%, CAI is in the better half of the industry, outperforming 76.33% of the companies in the same industry.
  • CAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

  • CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CAI has about the same amout of shares outstanding than it did 1 year ago.
  • CAI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CAI is higher compared to a year ago.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2023 2024 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 6.20 indicates that CAI is not in any danger for bankruptcy at the moment.
  • CAI's Altman-Z score of 6.20 is fine compared to the rest of the industry. CAI outperforms 75.76% of its industry peers.
  • A Debt/Equity ratio of 0.79 indicates that CAI is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.79, CAI is doing worse than 72.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 6.2
ROIC/WACCN/A
WACC8.98%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 9.93 indicates that CAI has no problem at all paying its short term obligations.
  • CAI has a better Current ratio (9.93) than 80.87% of its industry peers.
  • CAI has a Quick Ratio of 9.36. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 9.36, CAI is in the better half of the industry, outperforming 79.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.93
Quick Ratio 9.36
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

  • CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
  • CAI shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.67%.
  • CAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.64% yearly.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -37.72% on average over the next years. This is quite bad
  • CAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.63% yearly.
EPS Next Y-132.57%
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%
EPS Next 5Y-37.72%
Revenue Next Year76.15%
Revenue Next 2Y54.33%
Revenue Next 3Y42.64%
Revenue Next 5Y30.63%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAI. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 143.51, the valuation of CAI can be described as expensive.
  • Based on the Price/Forward Earnings ratio, CAI is valued cheaply inside the industry as 88.07% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.31, CAI is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 143.51
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • CAI's earnings are expected to decrease with -58.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CAI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CARIS LIFE SCIENCES INC

NASDAQ:CAI (1/15/2026, 8:00:02 PM)

After market: 27.12 0 (0%)

27.12

+0.7 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)N/A
Inst Owners37.15%
Inst Owner Change-0.01%
Ins Owners48.47%
Ins Owner Change-1.36%
Market Cap7.65B
Revenue(TTM)931.41M
Net Income(TTM)-998.17M
Analysts84.62
Price Target38.42 (41.67%)
Short Float %4.68%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1853.44%
Min EPS beat(2)-3845.54%
Max EPS beat(2)138.66%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)28.77%
Min Revenue beat(2)26.17%
Max Revenue beat(2)31.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.17%
PT rev (3m)-3.73%
EPS NQ rev (1m)13.66%
EPS NQ rev (3m)29.1%
EPS NY rev (1m)9.15%
EPS NY rev (3m)12.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)7.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 143.51
P/S 8.22
P/FCF N/A
P/OCF N/A
P/B 16
P/tB 16.67
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)0.19
Fwd EY0.7%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.3
BVpS1.7
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.93
Quick Ratio 9.36
Altman-Z 6.2
F-ScoreN/A
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-132.57%
EPS Next 2Y-83.58%
EPS Next 3Y-58.28%
EPS Next 5Y-37.72%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year76.15%
Revenue Next 2Y54.33%
Revenue Next 3Y42.64%
Revenue Next 5Y30.63%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.82%
EBIT Next 3Y47.6%
EBIT Next 5Y29.85%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A

CARIS LIFE SCIENCES INC / CAI FAQ

What is the fundamental rating for CAI stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAI.


Can you provide the valuation status for CARIS LIFE SCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Overvalued.


Can you provide the profitability details for CARIS LIFE SCIENCES INC?

CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CAI stock?

The Earnings per Share (EPS) of CARIS LIFE SCIENCES INC (CAI) is expected to decline by -132.57% in the next year.